Sionna falls after experimental drug misses mid-stage trial goal
SION•Other program updates
Sionna said SION-451 dual combinations met safety, tolerability and drug exposure goals in healthy volunteers, and the company is reviewing next steps.
Shares plunge after trial miss
Shares of biotech firm Sionna Therapeutics plunged 92% to $3.99 in premarket trading after its experimental cystic fibrosis drug failed a mid-stage study goal.
SION-719 misses main activity goal
The company said experimental cystic fibrosis drug SION-719 failed to improve sweat chloride levels, a key measure of CFTR protein function, in a mid-stage study.
Sionna said SION-719 will not advance as an add-on treatment to Vertex's standard therapy Trikafta after missing the study's main activity goal.
The trial showed a placebo-adjusted sweat chloride change of -1.0 mmol/L, with potential confounding factors under review.
Background and recent stock performance
Cystic fibrosis is an inherited disease that causes thick, sticky mucus to build up in the lungs and other organs.
As of the last close, the stock was up about 24% year to date.
